Abstract: This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen-specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.

Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation.

Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Abstract: The present invention relates to methods and compositions for inhibiting pancreatic &bgr; cell dysfunction and Fas-mediated apoptosis. The invention relates to recombinant vectors, including viral vectors, comprising nucleic acids molecules encoding inhibitors of interleukin-1&bgr; (IL-1&bgr;) and Fas-mediated apoptosis and the use of such vectors for transfer of said nucleic acid molecules into &bgr; cells. The invention encompasses genetically engineered &bgr; cells comprising nucleic acid molecules encoding inhibitors of IL-1&bgr; signal transduction. The invention further relates to methods for transplanting such genetically engineered &bgr; cells into a host recipient with a pancreatic disorder. The methods and compositions of the invention may be used to reduce Il-1&bgr; mediated &bgr; cell dysfunction and apoptosis, thereby reducing the insulitis associated with pancreatic disorders such as insulin dependent diabetes mellitus (IDDM).

Abstract: A method of detecting nucleic acid sequences in which polymers of selected oligonucleotide probes which are complementary to a region in a nucleic acid sequence that is to be detected are bound to a substrate. The polymers bound to the substrate contain multiple randomly repeated copies of a specific oligonucleotide probe and may be synthesized using enzymatic amplification techniques.